Month: September 2026

Abivax to Present Data on Obefazimod at United European Gastroenterology (UEG) Week 2026

Four oral presentations and three posters build upon Phase 3 ABTECT Maintenance and Induction programs in ulcerative colitis, long-term Phase 2 findings, and preclinical anti-fibrotic research

PARIS, France – September 30, 2026 – 10:05 PM CEST – Abivax SA (Euronext Paris: FR0012333284 – ABVX / Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, today announced that seven scientific abstracts on obefazimod, its lead drug candidate for the treatment of moderately to severely active ulcerative colitis (UC), will be presented at the United European Gastroenterology (UEG) Week 2026 meeting, taking place October 17–20, 2026, in Barcelona, Spain. These presentations will highlight data from the Phase 3 ABTECT Maintenance and Induction trials in UC, long-term follow-up from the Phase 2 program in UC, and preclinical research on obefazimod’s anti-fibrotic and anti-tumor activity.

“The data being presented at UEG Week add to the growing understanding of obefazimod and its potential in inflammatory bowel disease,” said Marc de Garidel, MBA, Chief Executive Officer of Abivax. “These findings reinforce our confidence in obefazimod’s potential to address significant unmet needs for patients living with inflammatory bowel disease.”

Chris Rabbat, PhD, Chief Medical Officer of Abivax, added, “The seven accepted abstracts reflect the breadth and maturity of the obefazimod program, spanning Phase 3 maintenance results, long-term Phase 2 efficacy and safety data, and preclinical findings on inflammation and fibrosis. We look forward to sharing these findings with the global gastroenterology community and highlighting the growing clinical and scientific evidence supporting obefazimod.”

Visit the publications page of Abivax’s website to view the presentations after the conclusion of the meeting.

Data to be Presented:

Date & Time	Session	Room	Abstract #	Title	Presenter
Oral Presentation
October 19, 10:50–11:00	Hot Topics in Clinical GI Research	D3	OP097	Efficacy and safety of obefazimod in patients with moderately to severely active ulcerative colitis: results from the Phase 3, randomized, double-blind, placebo-controlled, 44-week maintenance trial (ABTECT-Maintenance)	Prof. Bruce E. Sands, MD, MS Professor of Medicine at Icahn School of Medicine at Mount Sinai
October 19, 10:50–11:00	Molecular Trajectories of Disease and Drug Responses in IBD	A1	OP091	Obefazimod increases miR-124 expression to consistently modulate inflammation and fibrosis across preclinical models	Prof. Silvio Danese, MD, PhD Professor of Gastroenterology and Director of Gastroenterology and Gastrointestinal Endoscopy Unit at IRCCS San Raffaele Hospital
October 19, 12:00–12:10	Long-term Outcomes of Interventional Trials in IBD	A2	OP107	Long-term efficacy and persistence with obefazimod after dose de-escalation to 25 mg: 3-year interim analysis in patients with moderately to severely active ulcerative colitis completing Week 144, stratified by prior advanced therapy experience: results from the Phase 2 program	Prof. Bruce E. Sands, MD, MS Professor of Medicine at Icahn School of Medicine at Mount Sinai
October 20, 12:20–12:30	Looking into the Future: Novel Therapeutics in IBD, Part 2	B3	OP260	Efficacy of obefazimod in Phase 3 ABTECT-Maintenance trial: results of 44-week therapy in subsets of patients with and without prior inadequate response to advanced therapies	Prof. Silvio Danese, MD, PhD Professor of Gastroenterology and Director of Gastroenterology and Gastrointestinal Endoscopy Unit at IRCCS San Raffaele Hospital
Moderated Poster
October 18, 17:24–17:30	Outcomes from RCT in IBD (II)	Hall 7 – Poster Stage 2	MP0294	Efficacy, persistence, and safety of obefazimod in patients with moderately to severely active ulcerative colitis: 3-year interim analysis following dose de-escalation to 25 mg in the open-label maintenance Phase 2 study	Bram Verstockt, MD, PhD Associate Professor and Principal Investigator at KU Leuven
October 18, 17:36–17:42	Outcomes from RCT in IBD (II)	Hall 7 – Poster Stage 2	MP0296	Symptoms of bowel urgency and nocturnal bowel movements are linked with improvement in clinical outcomes among patients with moderately to severely active ulcerative colitis treated with obefazimod: pooled results from the 8-week ABTECT Phase 3 induction trials	David T. Rubin, MD Professor of Medicine and Chief, Gastroenterology, Hepatology and Nutrition at The University of Chicago
E-Poster
October 17, 9:00 – 9:00	IBD, including microscopic colitis	Hall 7	PP1180	Obefazimod reduces inflammation-driven tumor burden in a murine model of colitis-associated cancer	Prof. Silvio Danese, MD, PhD Professor of Gastroenterology and Director of Gastroenterology and Gastrointestinal Endoscopy Unit at IRCCS San Raffaele Hospital

About Abivax 

Abivax is a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Based in France and the United States, Abivax’s lead drug candidate, obefazimod (ABX464), is in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis.

Contact:
Patrick Malloy
SVP, Investor Relations
Abivax SA
patrick.malloy@abivax.com
+1 847 987 4878

Media Contact:
LifeSci Communications
Karissa Baltz, PhD
Associate Director
LSC_ABIVAX@lifescicomms.com

FORWARD-LOOKING STATEMENTS

This press release contains forward-looking statements, forecasts and estimates, including those relating to the Company’s business. Words such as “anticipate,” “expect,” “on track,” “potential,” “will” and variations of such words and similar expressions are intended to identify forward-looking statements. These forward-looking statements include statements concerning the potential therapeutic benefit of obefazimod and obefazimod’s potential to address significant unmet needs for patients living with inflammatory bowel disease, and other statements that are not historical fact. Although Abivax’s management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks, contingencies and uncertainties, many of which are difficult to predict and generally beyond the control of Abivax, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. A description of these risks, contingencies and uncertainties can be found in the documents filed by the Company with the French Autorité des Marchés Financiers pursuant to its legal obligations including its universal registration document (Document d’Enregistrement Universel) and in its Annual Report on Form 20-F for the fiscal year ended December 31, 2025 filed with the U.S. Securities and Exchange Commission on March 23, 2026, under the caption “Risk Factors.” These risks, contingencies and uncertainties include, among other things, the uncertainties inherent in research and development, future clinical data and analysis, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug candidate, as well as their decisions regarding labeling and other matters that could affect the availability or commercial potential of such product candidates, and the availability of funding sufficient for the Company’s foreseeable and unforeseeable operating expenses and capital expenditure requirements. Special consideration should be given to the potential hurdles of clinical and pharmaceutical development, including further assessment by the Company and regulatory agencies and IRBs/ethics committees following the assessment of preclinical, pharmacokinetic, carcinogenicity, toxicity, CMC and clinical data. Furthermore, these forward-looking statements, forecasts and estimates are made only as of the date of this press release. Readers are cautioned not to place undue reliance on these forward-looking statements. Abivax disclaims any obligation to update these forward-looking statements, forecasts or estimates to reflect any subsequent changes that the Company becomes aware of, except as required by law. Information about pharmaceutical products (including products currently in development) that is included in this press release is not intended to constitute an advertisement. This press release is for information purposes only, and the information contained herein does not constitute either an offer to sell or the solicitation of an offer to purchase or subscribe for securities of the Company in any jurisdiction. Similarly, it does not give and should not be treated as giving investment advice. It has no connection with the investment objectives, financial situation or specific needs of any recipient. It should not be regarded by recipients as a substitute for exercise of their own judgment. All opinions expressed herein are subject to change without notice. The distribution of this document may be restricted by law in certain jurisdictions. Persons into whose possession this document comes are required to inform themselves about and to observe any such restrictions.

Attachment

• 2026_09_30_Abivax to Present Data on Obefazimod at UEG Week 2026

ZUG, Switzerland, Sept. 30, 2026 (GLOBE NEWSWIRE) — Lithium Argentina AG (“Lithium Argentina” or the “Company”) (TSX: LAR) (NYSE: LAR) announced the results of a Scoping Study (the “Scoping Study”) for the Cauchari-Olaroz Stage 2 Expansion Project (“Stage 2” or the “Expansion Project”) in Jujuy Province, Argentina.

The Scoping Study supports a brownfield expansion designed to produce an additional 45,000 tonnes per annum (“tpa”) of lithium carbonate at Cauchari-Olaroz. The Scoping Study generated an after-tax NPV_8% of $3.1 billion and IRR of 28.5% using a lithium carbonate price of $18,000/t.

Concurrently, the Company is proceeding with plans to accelerate an initial 10,000 tpa (the “Initial Phase”) of the planned 45,000 tpa Stage 2 expansion using adsorption Direct Lithium Extraction (“DLE”) technology, subject to receipt of applicable regulatory approvals and permits, including those required in connection with the procurement and deployment of certain technology and equipment. The initial module would provide an opportunity to accelerate incremental production, further demonstrate adsorption DLE performance on a commercial scale and support the phased development of Stage 2. This optionality allows the Company to continue optimizing process selection based on recovery, capital intensity, operating costs and execution considerations while leveraging the existing infrastructure and operating platform at Cauchari-Olaroz.

Highlights:

• 45,000 tpa Lithium Carbonate Equivalent (“LCE”) Expansion: Stage 2 is designed to produce 45,000 tpa of LCE, increasing total Cauchari-Olaroz production capacity to approximately 85,000 tpa, with an expected 40-year operating life.
• Compelling Economics: At $18,000/t lithium carbonate, after-tax NPV_8% of $3.1 billion and IRR of 28.5%.
• Competitive Cost Profile: Estimated operating costs of US$5,006/t of lithium carbonate, supported by higher process recoveries and brownfield synergies.
• Flexible Hybrid DLE Processing: The characteristics of the Cauchari-Olaroz brine and existing infrastructure provide flexibility to optimize the processing approach based on cost, technical performance and environmental considerations.
• Phased Development Approach:  Accelerated initial 10,000 tpa of the planned 45,000 tpa Stage 2 expansion using adsorption-based DLE technology, expected online during 2028, subject to permitting and regulatory approvals, including the required approvals in Argentina and China related to the deployment and transfer of the adsorption-based processing technology. The accelerated timing of this initial capacity is not reflected in the Scoping Study or its economic analysis.
• Capital-Efficient Expansion: Initial capital cost of approximately US$1.0 billion, reflecting the advantages of expanding an established operating asset.
• RIGI Approved: The project has received approval under Argentina’s Régimen de Incentivo para Grandes Inversiones (“RIGI”), providing long-term fiscal stability and investment incentives that enhance long-term project economics.
• Financially Supported by Stage 1: The Company expects to fund Stage 2 through internally generated cash flow and project-level debt, leveraging the cash flow generation of the existing operation.

Sam Pigott, CEO of Lithium Argentina, commented:

“The Scoping Study confirms the significant value in expanding Cauchari-Olaroz, with an after-tax NPV of US$3.1 billion. Building on the strong performance of the existing operation, we will pursue a flexible, modular approach to Stage 2 development.

“We are moving immediately to advance a 10,000 tpa first phase using adsorption technology. It is the fastest and most capital-efficient path to incremental production, leveraging the existing infrastructure and permits, with a target for first production within two years.

“With RIGI approval secured and multiple funding pathways available, we have significant flexibility in how we advance Cauchari-Olaroz. More broadly, strong cash flow from the operation and the formation of the PPG joint venture position us to advance both of our core assets in parallel with our partners, with a disciplined focus on deploying capital where it generates the strongest returns for shareholders.”

A technical report, prepared by Golder Associates (“Golder”), in accordance with National Instrument 43-101 Standards of Disclosure for Mineral Projects (“NI 43-101”) and Subpart 1300 of Regulation S-K (“S-K 1300”), will be filed within 45 days. Unless otherwise indicated, all figures are in U.S. dollars and on a 100% basis.

Stage 2 Scoping Study Results – Summary¹

Key Results
Operating Profile
Existing Capacity	40,000 tpa LCE
Scoping Study Expansion Annual Production under RIGI	45,000 tpa LCE
Total Cauchari-Olaroz Production Capacity after Expansion	85,000 tpa LCE
Scoping Study Expansion Project life	40 years
Processing	Hybrid (SX) DLE
Economic Parameters2
Lithium Carbonate Price	$18,000 / t
NPV8%	$3.1 B
IRR	28.5%
Payback	5 years
Financial Metrics
Capital Costs	$1.0 B
Initial Capital Intensity	$22,530 / t
Operating Costs	$5,006 / t

__________________________

¹ All dollar figures are in United States dollars and are on a 100% basis unless otherwise indicated.
² After-tax economic results.

Initial Phase Development Strategy 

The Scoping Study evaluates the economics of a single 45,000 tpa expansion.  The recovery method evaluated in the Scoping Study is based on brine pre-concentration followed by solvent extraction, and the capital costs, operating costs, production schedule and economic analysis presented have been developed on that basis. The Company intends to advance Stage 2 through a phased development strategy designed to reduce execution risk and advance the overall development plan. The Initial Phase will allow for an accelerated 10,000 tpa, leveraging existing infrastructure and permits.

Key elements of the Initial Phase include:

• Permitting: The Company is advancing the required permitting and regulatory approvals for the Initial Phase, including the required approvals in Argentina and China related to the deployment and transfer of the adsorption-based processing technology. All required permits and regulatory approvals are currently targeted to be received during the first half of 2027.
• Equipment supply: Engineering of the modular plant has commenced in China, which will subsequently be manufactured, shipped and assembled at the Cauchari-Olaroz site. Export of this technology from China is subject to Chinese regulatory authorization, which has not yet been obtained. Module engineering is proceeding in advance of receipt of this authorization.
• Early works: Early-stage site works, including additional brine well development, activities that will also support the broader Stage 2 expansion, are underway to support the expansion Initial Phase.

Specific capital expenditure requirements for the Initial Phase will be available once detailed engineering is completed later this year, with the 2027 capex budget to be finalized accordingly. The capital required for the Initial Phase is not expected to increase the Scoping Study’s total estimated capital expenditure. The phased approach also preserves flexibility to pace the broader expansion in line with market conditions, while allowing the Initial Phase to satisfy the minimum investment requirements under RIGI.

The proposed accelerated development of the Initial Phase, including its capital requirements and development schedule, is not reflected in the Scoping Study or its economic analysis. 

Stage 2 Development Strategy 

The Scoping Study establishes a technically de-risked, industry-comparable economic base case for the full 45ktpa expansion using SX, a proven DLE technology available for study now. The Initial Phase reflects the Company’s preferred near-term execution path, selected for its cost and permitting advantages. These activities are expected to include additional production and exploration drilling, brine gathering and pipeline infrastructure, industrial water development and site preparation. Advancing this work alongside the initial module is expected to support the subsequent development of the remaining Stage 2 capacity.

The remaining 35,000 tpa of Stage 2 capacity will complete the expansion to 45,000 tpa, increasing total production capacity at Cauchari-Olaroz to approximately 85,000 tpa. The expansion is designed to integrate DLE capacity with the existing evaporation-based process, increasing lithium recovery while continuing to utilize the established evaporation ponds and lithium carbonate processing facilities.

The ability to expand adsorption technology beyond the Initial Phase of 10,000 tpa — for part or all of the remaining expansion — is contingent on further technical work, including demonstrating water consumption performance on a commercial scale and/or securing additional water resources. Adsorption has economic benefits, as well as a reduced footprint and water consumption performance will be assessed during operation of the Initial Phase of 10,000 tpa and is expected to help determine the applicability of adsorption technology for the balance of the expansion.

The Environmental Impact Assessment (“EIA”) application for the full 45,000 tpa expansion has been submitted, with environmental approval currently anticipated during 2027.

Operating Costs

Average life of project costs for the 45,000 tpa expansion are summarized below.

Operating Costs – Expansion Project	($ per tonne)
Category
Reagents	$1,734
Power & Energy	$472
Labour	$609
Maintenance	$408
Salts harvesting & Disposal	$776
G&A	$213
Others	$555
Sub-Total	$4,768
Contingency	$238
Total	$5,006

Capital Costs

The capital cost for life of Stage 2 is estimated at $1.0 billion, inclusive of contingency, based on construction and are based on Argentine costs for labor and materials. This reflects a total capital intensity of approximately $22,500 per tonne of annual LCE production.

The estimated capital cost benefits from leveraging existing infrastructure, utilities and operating facilities at Cauchari-Olaroz are summarized below:

Capital Cost – Life of Project	($ millions)
Wellfield, Ponds and Brine Systems	$421
Processing Plants	$356
Infrastructure/Power/TMA Costs	$208
Owner Costs	$28
Total Capital Costs (including contingency)3	$1,013

The Scoping Study contemplates a staged development underpinned by both existing site infrastructure and new process facilities. Wellfield, ponds and brine system infrastructure are largely related to the construction of these items. Plants capital costs include all the capital for the lithium plant, including: DLE plant, purification plant, utilities and LCE processing facilities.

Infrastructure, Power/Tailing Management Area (“TMA”) and energy costs relate to water supply, transformers, warehouse office buildings, camps, effluent plant, and waste yard infrastructure, power lines, fuel plant and emergency generation and salts disposal costs. 

__________________________

³ Initial capital costs include contingency applied by cost category.

RIGI

Stage 2 has received approval under RIGI. The Scoping Study incorporates the benefits associated with the approved RIGI framework, including enhanced fiscal stability, a reduced corporate income tax rate, accelerated depreciation and foreign exchange benefits, strengthening the project’s long-term economics.

Stage 2 Valuation Price Sensitivities and Returns

The financial results are derived from inputs based on an annual production schedule included in the Scoping Study with an incremental after-tax NPV_8% of $3 billion. A sensitivity analysis of long-term lithium carbonate price on the economic results for the 45,000 tpa of LCE over a 40-year operating period is summarized below.

Key Parameters	Scenario 1	Scenario 2 (Base Case)	Scenario 3
Lithium Carbonate Price	$16,000/t	$18,000/t	$20,000/t
After-Tax NPV8%	$2.5B	$3.1B	$3.7B
After-Tax IRR	25.3%	28.5%	31.4%
Payback (years)	~6	~5	~5

Mineral Resource

The January 2026 resource update supports Cauchari-Olaroz’ large-scale and high-quality lithium brine Deposit. Total M&I resources increased LCE estimates by 42% compared to the 2019 estimate, including a significant increase in Measured resources reflecting additional drilling, incorporation of operating data, increased resource area and basin-wide hydrogeological modeling. The improved geological and aquifer understanding strengthens confidence in the resource base and supports the Stage 2 expansion.

Mineral Resource Estimation 

The Mineral Resources for Stage 2 as described in the Scoping Study are summarized in the table below.

Resource Category	Cauchari-Olaroz
	Li (mg/L)	LCE (Mt)
Measured	557	16.8
Indicated	571	11.3
Total M&I	562	28.1
Inferred	567	9.6

Notes:

1. LCE is calculated using the Li:LCE factor = 5.322785 multiplied by the mass of Lithium
2. Mineral Resources are not mineral reserves and do not have demonstrated economic viability. There is no certainty that all or any part of the mineral resource will be converted to mineral reserves.
3. The Mineral Resource Estimate represented as LCE for Cauchari-Olaroz has an effective date of January 1, 2026, and it is expressed relative to the delineated resource area.
4. The qualified person for the Mineral Resource Estimate is Mark King, PhD PGeo., FGC, a “qualified person” as defined in National Instrument 43-101, who is independent of the Company. The qualified person is not aware of any known legal, political, environmental or other risks that could materially affect the potential development of the Mineral Resources.
5. No cut-off values have been applied to the resource estimate.
6. Stage 2 economics are not based on Inferred Mineral Resources.

Next Steps

The Company intends to continue advancing Stage 2 through engineering, permitting and early development activities while progressing toward a future development decision. Key activities are expected to include:

• Advance Early Works Strategy: Continue early development activities under existing permits, including production and exploration drilling, industrial water development and site preparation activities.
  • Continue detailed engineering and optimization of the Stage 2 expansion, incorporating operational learnings from the existing Cauchari-Olaroz operation.
• Modular DLE Development: Progress project and engineering of the initial modular DLE facility, expected to produce approximately 10,000 tpa LCE.
• Environmental Permitting: Advance the EIA for the full 45,000 tpa expansion.
• Project Financing: Advance financing activities consistent with the Company’s strategy to fund Stage 2 through internally generated cash flow and project-level debt.

Non-IFRS Measures

Operating cash costs per tonne are non-IFRS measures or ratios and do not have a standardized meaning under IFRS and may not be comparable to similar financial measures used by other issuers.  The Company believes that this measure provides investors with an improved ability to evaluate the prospects of the Company and Stage 2.  As Stage 2 is not in production, operating cash cost may not be reconciled to the nearest comparable measures under IFRS and nor an equivalent historical non-IFRS measure for Stage 2.

Operating Cash Cost	$ per tonne of LCE
Projected Operating Cash Cost – Stage 2	$5,0064

Scientific & Technical Information and Qualified Persons

The scientific and technical information in this news release has been reviewed and approved by the independent qualified persons (“QPs”) listed below, each of whom is a “qualified person” as defined in NI 43-101.

• James Wang, P.E., Director, Golder.
• Mark King, PhD. PGeo., FGC
• David Burga, P. Geo

Report Filing

The Company will file a technical report prepared in accordance with NI 43-101with respect to the Scoping Study on SEDAR+ (http://www.sedarplus.ca and on the Company’s website (http://www.lithium-argentina.com) within 45 days of this news release.

For U.S. reporting purposes, the Company intends to furnish this news release on Form 6-K and to file a Technical Report Summary (TRS) prepared in accordance with Subpart 1300 of Regulation S-K. The TRS will be prepared by, or under the supervision of, a qualified person as defined in S-K 1300 and will summarize the material scientific and technical information supporting the Scoping Study.

__________________________

⁴ Operating cost is defined as the net direct cash cost, or simply the cost of production including the costs of mining, processing, transportation, marketing, and onsite administration.

ABOUT LITHIUM ARGENTINA

Lithium Argentina owns and actively manages significant interests in large-scale lithium assets, a key material used in the production of lithium-ion batteries, electric vehicles, and battery energy storage systems (BESS). The Company, in partnership with Ganfeng operates the Cauchari-Olaroz lithium brine operation in the Jujuy province of Argentina and is advancing PPG in the Salta province of Argentina. Lithium Argentina currently trades on the TSX and on the NYSE under the ticker “LAR”.

For further information contact:
Investor Relations
Telephone: +1 778-653-8092
Email: kelly.obrien@lithium-argentina.com
Website: http://www.lithium-argentina.com

FORWARD-LOOKING INFORMATION

This news release contains “forward-looking information” and “forward-looking statements” (which we refer to collectively as forward-looking information) under the provisions of applicable securities legislation. Forward-looking information can be identified by the use of words such as seek”, “anticipate”, “plan”, “continue”, “estimate”, “expect”, “may”, “will”, “project”, “predict”, “propose”, “potential”, “target”, “intend”, “could”, “might”, “should”, “believe”, “scheduled”, “implement” and similar words or expressions. All statements, other than statements of historical fact, are forward-looking information. Forward-looking information in this news release include, without limitation, information with respect to the following matters or the Company’s expectations relating to such matters:  the timing of the filing of the technical report for the Scoping Study and TRS; and the anticipated benefits therefrom; , including the involvement of third-party investors, the timing and filing of applicable permitting applications; the use and effects of DLE technology; the results of the Scoping Study, including, without limitation, expected project life, production, capital and operating costs, IRR, NPV and other economic and operating parameters of Stage 2 at Cauchari; mineral resource estimates; and the timing and amount of future production and expected capacity of production of Stage 2; anticipated costs of the Initial Phase, timing of approvals and authorizations thereforand the potential benefits derived therefrom;  expectations with respect to funding the Stage 2 expansion; the development strategy for Stage 2 and the Initial Phase; expected benefits of RIGI approval and possible multiple pathways to fund development and the actions outlined under “Next Steps”.

Forward-looking information may involve known and unknown risks, assumptions and uncertainties which may cause the Company’s actual results or performance to differ materially. This information reflects the Company’s current views with respect to future events and is necessarily based upon a number of assumptions that, while considered reasonable by the Company today, are inherently subject to significant uncertainties and contingences, and accordingly, the Company can give no assurance that these assumptions and expectations will prove to be correct. With respect to forward-looking information included in this news release, the Company has made assumptions regarding, among other things: current technological trends; the business relationship between the Company and Ganfeng; ability to fund its operations; the ability to operate in a safe and effective manner; uncertainties relating to obtaining and/or maintaining mining, exploration, development, environmental and other permits or approvals in Argentina; demand for lithium; impact of increasing competition in the lithium business, including the Company’s competitive position in the industry; general economic conditions; stability and support of legislative, regulatory and community environment in the jurisdiction where it operates; estimates of and changes to market prices for lithium and commodities; estimates costs for the project or operation; estimates of mineral resources and mineral reserves, including whether mineral resources will ever be developed into mineral reserves; reliability of technical data; and the ability to achieve full production; and accuracy of budget and estimates. Forward-looking information also involves known and unknown risks that may cause actual results to differ materially, these risks include, among others: risk inherent to studies such as the Scoping Study, which are subject to significant assumptions and a high degree of uncertainty; risk that the Company may not be able to obtain the anticipated benefits from the RIGI regime as anticipated, or at all; risk that the Company may not be able to fund or finance the development of Stage 2 and/or the Initial Phase as contemplated, or at all;  risk that the Company will not be able to implement DLE technology; the operations may not operate and produce as planned; cost overruns; market prices affecting development of the operation; risks associated with co-ownership arrangements; risks with ability to successfully secure adequate financing if necessary; risks to the growth of the lithium markets; lithium prices; inability to obtain any future required governmental permits and approvals and that operations may be limited by government-imposed limitations; technology risk; inability to achieve and manage expected growth; political risk associated with foreign operations, including co-ownership arrangements with foreign domiciled partners; emerging and developing market risks; operational risks; changes in government regulations; changes in environmental requirements; failure to obtain or maintain necessary licenses, permits or approvals; insurance risk; receipt and security of mineral property titles and mineral tenure risk; changes in project or operation parameters; uncertainties associated with estimating mineral resources and mineral reserves, including uncertainties regarding assumptions underlying such estimates; whether mineral resources will ever be converted into mineral reserves; opposition to the; geological or technical or processing problems; liabilities and risks; health and safety risks; unanticipated results; unpredictable weather; unanticipated delays; reduction in demand for lithium; inability to generate profitable operations; restrictive covenants in debt instruments; intellectual property risks; dependency on key personnel; currency and interest rate fluctuations; and volatility in general market and industry conditions. Additional risks, assumptions and other factors are set out in the Company’s management discussion analysis, most recent Annual Report on Form 20-F, and other disclosure documents copies of which are available on SEDAR+ at www.sedarplus.ca

Although the Company has attempted to identify important risks and assumptions, given the inherent uncertainties in such forward-looking information, there may be other factors that cause results to differ materially. Forward-looking information is made as of the date hereof and the Company does not intend, and expressly disclaims any obligation to, update or revise the forward-looking information contained in this news release, except as required by law. Accordingly, readers are cautioned not to place undue reliance on forward-looking information. 

BURLINGTON, Mass., Sept. 30, 2026 (GLOBE NEWSWIRE) — Progress Software (Nasdaq: PRGS), a member of the Russell 2000 Index and an AI infrastructure software leader, today announced its financial results for the fiscal third quarter ended on August 31, 2026.

The company’s earnings release and a supplemental slide presentation can be accessed via the Investor Events & Presentations link on the Progress Investor Relations webpage. Progress will host a conference call today at 5:00 p.m. ET to discuss its results and outlook.

Conference Call Details

• A live webcast of the call will be available at this link.
• To access the conference call by phone, use this link to retrieve dial-in details. Participants are encouraged to dial in 15 minutes before the scheduled start time.
• A replay of the conference call and supporting materials will be available on the Progress Investor Relations webpage following the live event.

About Progress Software
Progress Software (Nasdaq: PRGS) provides the context and control organizations need to reliably extract value from AI—context drawn from an organization’s data, content and workflows, and control over the security, governance and cost of their AI initiatives. Learn how hundreds of thousands of businesses, powering the work of tens of millions of professionals worldwide, realize value from trusted, enterprise-ready AI at www.progress.com.

Progress is a trademark or registered trademark of Progress Software Corporation and/or its subsidiaries or affiliates in the U.S. and other countries. Any other names contained herein may be trademarks of their respective owners.  

Investor Contact:	Press Contact:
Michael Micciche	Jeff Young
Progress Software	Progress Software
+1 781-850-8450	+1 781-280-4000
Investor-Relations@progress.com	PR@progress.com

Source: Progress Software Corporation

FREMONT, Calif., Sept. 30, 2026 (GLOBE NEWSWIRE) — ACM Research, Inc. (“ACM”) (NASDAQ: ACMR), a leading supplier of wafer and panel processing solutions for semiconductor and advanced packaging applications, today announced management’s participation in the 18th Annual CEO Investor Summit 2026, being held Tuesday, October 13^th, 2026 at the St. Regis Hotel in San Francisco, California.

The presentation material utilized during the CEO Investor Summit will be made accessible on the events page of the Company’s IR website at https://ir.acmr.com/news-events/events.

About the 18^th Annual CEO Investor Summit 2026

The CEO Investor Summit is held annually each year during the SEMICON West industry trade show. Collectively hosted and funded by participating companies, the CEO Investor Summit features a “round-robin” format consisting of small group meetings with company management teams. During the event, investors and analysts will have the opportunity to meet with the majority of the 11 management teams during the small group meeting sessions and networking events.

The 11 management teams collectively hosting the 18^th Annual CEO Investor Summit include: ACM Research (ACMR), Aehr Test Systems (AEHR), Alpha & Omega Semiconductor (AOSL), Cohu, Inc. (COHU), FormFactor (FORM), Ichor Systems (ICHR), InTEST Corporation (INTT), Kulicke & Soffa (KLIC), Photronics (PLAB), QuickLogic (QUIK), and SkyWater Technology, an IonQ company (IONQ). B Riley Securities, Jefferies and Stifel are sponsors of the conference.

Attendance at the CEO Investor Summit is by invitation only and is available solely to accredited investors and publishing research analysts. As space is limited, please RSVP early. Hosts reserve the right to limit attendance as necessary. Last day for registration is October 2, 2026.

RSVP Contacts for 18^th Annual CEO Investor Summit 2026

To RSVP for the CEO Investor Summit, please visit the CEO Summit Events website or contact either of the event co-chairs:

Laura J. Guerrant-Oiye	Claire E. McAdams
Phone: (808) 960-2642	Phone: (530) 265-9899
Email: lauraoiye@gmail.com	Email: claire@headgatepartners.com

About ACM Research, Inc.

ACM develops, manufactures and sells semiconductor process equipment spanning cleaning, electroplating, stress-free polishing, vertical furnace processes, track, PECVD, and wafer- and panel-level packaging tools, enabling advanced and semi-critical semiconductor device manufacturing. ACM is committed to delivering customized, high-performance, cost-effective process solutions that semiconductor manufacturers can use in numerous manufacturing steps to improve productivity and product yield. For more information, visit www.acmr.com.

© ACM Research, Inc. ACM Research logo is a trademark of ACM Research, Inc. For convenience, these trademarks appear in this press release without ™ symbols, but that practice does not mean ACM will not assert, to the fullest extent under applicable law, its rights to such trademarks. All other trademarks are the property of their respective owners.

For investor and media inquiries, please contact:

In the United States:	The Blueshirt Group Steven C. Pelayo, CFA +1 (360) 808-5154 steven@blueshirtgroup.co
In China:	The Blueshirt Group Asia Gary Dvorchak, CFA gary@blueshirtgroup.co

New Data Analysis from Phase 2a Clinical Trial in Alzheimer’s Disease (AD) Indicating That Laromestrocel Treatment May Reduce Neuroinflammation in the Brain, A Core Driver of AD Pathogenesis, Published on medRxiv

MIAMI, Sept. 30, 2026 (GLOBE NEWSWIRE) — Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today announced that it will participate in three upcoming Longevity/Aging investment conferences.

13th Aging Research and Drug Discovery Meeting (ARDD) to be held October 1-3, 2026 in Boston

Abundance Longevity Trip to be held October 7-11, 2026 (virtual participation)

Longevity Partnering Forum to be held October 19-20, 2026 in South San Francisco

Longevity and Aging-Related Frailty
The Company intends to pursue funding sources and other potential revenue opportunities to advance laromestrocel in longevity and Aging-related Frailty. Results from a Phase 2b clinical trial demonstrated that intravenous laromestrocel improved the physical condition of patients with age-related clinical frailty after nine months, compared to placebo. These results were published in Cell Stem Cell in February 2026. Further, based on these clinical trial results, Longeveron announced in August 2026 that it was selected from over 600 worldwide applicants to advance to the final phase of the XPRIZE Healthspan competition as a Milestone 2 Awardee team. Longeveron received the $1,000,000 Milestone 2 Award to be used towards the future competition clinical trial in accordance with the XPRIZE competition rules, with the opportunity to compete for the XPRIZE Grand Prize of up to $81 million.

New Analysis of Laromestrocel Phase 2a Data in Alzheimer’s Disease Published on medRxiv
The Company has recently published a new manuscript as a pre-print in medRxiv, detailing post-hoc exploratory analysis from the Company’s Phase 2a randomized CLEAR MIND study (NCT05233774; n=49) in AD that indicated laromestrocel treatment may reduce neuroinflammation in the brain—a core driver of AD pathogenesis, using free water MRI imaging.

This is a preprint and has not yet completed peer review. Laromestrocel is an investigational product and has not been approved by the FDA or any other regulatory agency.

Read the full preprint: https://www.medrxiv.org/content/10.64898/2026.09.16.26363132v1

Key findings:

• Laromestrocel inhibited the progression of neuroinflammation, with the strongest effects in regions at the core of Alzheimer’s pathology, including the left hippocampus (p<0.001 in both the 25M and 100M cell dose groups), as well as the temporal and parietal cortex.
• Reduced neuroinflammation correlated with less brain atrophy and with improved clinical scores, particularly cognition as measured by MoCA.
• Treated participants showed lower plasma neurogranin, consistent with reduced synaptic loss.
• Blood biomarker analyses point to a convergent, multimodal mechanism of action involving peripheral immune engagement.

Together, these results support the hypothesis that laromestrocel’s potential anti-inflammatory effects may help protect brain tissue and function in Alzheimer’s disease. If confirmed, durable anti-inflammatory effects may also be useful in combatting chronic inflammation in aging, or “inflammaging”.

These new results follow publication of main CLEAR MIND trial results in Nature Medicine in 2025. https://www.nature.com/articles/s41591-025-03559-0

About laromestrocel (Lomecel-B^®)
Laromestrocel is a living cell product made from specialized cells isolated from the bone marrow of young, healthy adult donors. These specialized cells, known as mesenchymal stem cells (MSCs), are essential to the human endogenous biological repair mechanism. MSCs have the potential to perform a number of complex functions in the body and possibly support tissue repair and regenerative signaling pathways. They also may respond to sites of injury or disease and may secrete bioactive factors that are immunomodulatory and regenerative. We believe laromestrocel MSCs may have multiple potential mechanisms of action that may lead to anti-inflammatory, pro-vascular regenerative responses, and therefore may have broad application for a range of rare and aging related diseases.

About Longeveron Inc.
Longeveron is a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. The Company’s lead investigational product is laromestrocel (Lomecel-B®), an allogeneic mesenchymal stem cell (MSC) therapy product isolated from the bone marrow of young, healthy adult donors. We believe laromestrocel has multiple potential mechanisms of action encompassing pro-vascular, pro-regenerative, anti-inflammatory, and tissue repair and healing effects with broad potential applications across a spectrum of disease areas. Longeveron is pursuing four pipeline indications: hypoplastic left heart syndrome (HLHS), Alzheimer’s disease, Pediatric Dilated Cardiomyopathy (DCM) and Aging-related Frailty. Laromestrocel development programs have received five distinct and important FDA designations: for the HLHS program – Orphan Drug designation, Fast Track designation, and Rare Pediatric Disease designation; and, for the AD program – Regenerative Medicine Advanced Therapy (RMAT) designation and Fast Track designation. For more information, visit www.longeveron.com or follow Longeveron on LinkedIn, X, and Instagram.

Forward-Looking Statements
Certain statements in this press release that are not historical facts are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, which reflect management’s current expectations, assumptions, and estimates of future operations, performance and economic conditions, and involve known and unknown risks, uncertainties, and other important factors that could cause actual results, performance, or achievements to differ materially from those anticipated, expressed, or implied by the statements made herein. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate, including our ability to pursue funding sources and potential revenue opportunities to advance laromestrocel in longevity and Aging-related frailty; our expectations regarding the review and exploration of all options and their potential impact on shareholder value; our ability to engage an investment bank or other strategic advisor; the continued listing of our Class A common stock on Nasdaq; our expectations regarding the future of the Company’s operations, including our clinical, development and commercialization activities; our plans to implement cash conservation measures to reduce operating expenses; and other statements regarding future events. Forward-looking statements are generally identifiable by the use of forward-looking terminology such as “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expects,” “intend,” “looks to,” “may,” “on condition,” “plan,” “potential,” “predict,” “preliminary,” “project,” “see,” “should,” “target,” “will,” “would,” or the negative thereof or comparable terminology, although not all forward-looking statements contain these words, or by discussion of strategy or goals or other future events, circumstances, or effects. Additional factors that could cause actual results to differ materially from those expressed or implied in any forward-looking statements in this release include, but are not limited to, the risk that the exploration of strategic options may not result in any definitive transaction or enhance shareholder value or may create uncertainty that may adversely affect our business, financial condition, results of operations, or shareholder and investor perception; the ability of our clinical trials to demonstrate safety and efficacy of our investigational product candidates, and other positive results; our ability to successfully transition toward a more capital-efficient, asset-light operating model; our ability to secure one or more strategic licensing partnerships for laromestrocel in our development programs; our ability to reach alignment with the FDA and other regulatory authorities on a potential path toward regulatory approval; the availability of evidence from our ongoing and future preclinical studies and clinical trials sufficient to support the Company filing a BLA for the investigational product candidate for one or more indications; the timing and focus of our ongoing and future preclinical studies and clinical trials, and the reporting of data from those studies and trials; market and other conditions, our cash position and need to raise additional capital, the difficulties we may face in obtaining access to capital, and the dilutive impact it may have on our investors; our financial performance, and ability to continue as a going concern; the period over which we estimate our existing cash and cash equivalents will be sufficient to fund our future operating expenses and capital expenditure requirements; the size of the market opportunity for certain of our investigational product candidates, including our estimates of the number of patients who suffer from the diseases we are targeting; our ability to scale production and commercialize the investigational product candidate for certain indications; the success of competing therapies that are or may become available; the beneficial characteristics, safety, efficacy and therapeutic effects of our investigational product candidates; our ability to obtain and maintain regulatory approval of our investigational product candidates in the U.S. and other jurisdictions; our plans relating to the further development of our investigational product candidates, including additional disease states or indications we may pursue; our plans and ability to obtain or protect intellectual property rights, including extensions of existing patent terms where available and our ability to avoid infringing the intellectual property rights of others; the need to hire additional personnel and our ability to attract and retain such personnel; and our estimates regarding expenses, future revenue, capital requirements and needs for additional financing.

Further information relating to factors that may impact the Company’s results and forward-looking statements are disclosed in the Company’s filings with the Securities and Exchange Commission, including Longeveron’s Annual Report on Form 10-K for the year ended December 31, 2025, filed with the Securities and Exchange Commission on March 17, 2026, its Quarterly Reports on Form 10-Q, and its Current Reports on Form 8-K. The Company operates in a highly competitive and rapidly changing environment; therefore, new factors may arise, and it is not possible for the Company’s management to predict all such factors that may arise nor assess the impact of such factors or the extent to which any individual factor or combination thereof, may cause results to differ materially from those contained in any forward-looking statements. The forward-looking statements contained in this press release are made as of the date of this press release based on information available as of the date of this press release, are inherently uncertain, and the Company disclaims any intention or obligation, other than imposed by law, to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

Investor and Media Contact:
Derek Cole
Investor Relations Advisory Solutions 
derek.cole@iradvisory.com

SALT LAKE CITY, Sept. 30, 2026 (GLOBE NEWSWIRE) — Medallion Bank (Nasdaq: MBNKO), an FDIC-insured bank providing consumer loans for the purchase of recreational vehicles, boats, and home improvements, along with loan origination services to fintech strategic partners, announced today that it has closed a public offering of 2,200,000 additional shares of its Fixed-Rate Reset Non-Cumulative Perpetual Preferred Stock, Series G, par value $1.00 per share, with a liquidation amount of $25 per share (the “Series G Preferred Stock”) and an aggregate liquidation amount of $55 million. The offering priced on September 23, 2026. The underwriters have also been granted a 30-day option to purchase up to an additional 330,000 shares of the Series G Preferred Stock solely to cover over-allotments, if any.

Medallion Bank’s Series G Preferred Stock is traded on the Nasdaq Capital Market under the ticker symbol “MBNKO.” Medallion Bank remains a wholly owned subsidiary of Medallion Financial after the completion of the offering.

Medallion Bank intends to use the net proceeds from this offering for general corporate purposes, which may include, among other things, redeeming some or all of its outstanding Senior Series E Non-Cumulative Perpetual Preferred Stock (the “Series E Preferred Stock”), subject to the prior approval of the Federal Deposit Insurance Corporation.

Piper Sandler & Co., Lucid Capital Markets, LLC, Muriel Siebert & Co., LLC, A.G.P. / Alliance Global Partners, and Ladenburg Thalmann & Co. Inc. are acting as joint book-running managers. William Blair & Company, L.L.C., InspereX LLC, B. Riley Securities, Inc., and Clear Street LLC are acting as lead managers.

The offering of the Medallion Bank’s Series G Preferred Stock was exempt from the registration requirements of the Securities Act of 1933 pursuant to Section 3(a)(2) of that Act and was made only by means of an offering circular. This press release is for informational purposes only and does not constitute an offer to sell or the solicitation of an offer to buy securities, and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction. The securities are neither insured nor approved by the Federal Deposit Insurance Corporation or any other Federal or state regulatory body.

The final offering circular relating to the offering is available at medallionbankoffering.com. In addition, copies of the final offering circular may also be obtained from: Piper Sandler & Co.; Attn: Debt Capital Markets, 1251 Avenue of the Americas, 6th Floor, New York, 10020, or by email at fsg-dcm@psc.com.

About Medallion Bank

Medallion Bank specializes in providing consumer loans for the purchase of recreational vehicles, boats, and home improvements, along with loan origination services to fintech strategic partners. The Bank works directly with thousands of dealers, contractors and financial service providers serving their customers throughout the United States. Medallion Bank is a Utah-chartered, FDIC-insured industrial bank headquartered in Salt Lake City and is a wholly owned subsidiary of Medallion Financial Corp.

For more information, visit www.medallionbank.com

This press release contains “forward-looking statements”, which reflect Medallion Bank’s current views with respect to future events and which address matters that are, by their nature, inherently uncertain and beyond Medallion Bank’s control. These statements are often, but not always, made through the use of words or phrases such as “expect” and “intend” or the negative version of those words or other comparable words or phrases of a future or forward-looking nature. These statements relate to the offering of shares of the Series G Preferred Stock, the anticipated use of the net proceeds by Medallion Bank and the grant to the underwriters of an option to purchase additional shares of the Series G Preferred Stock. No assurance can be given that Medallion Bank will decide to redeem its Series E Preferred Stock or, if it does, the amount to be redeemed and the timing of redemption and required regulatory approval. Medallion Bank undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. For a description of certain risks to which Medallion Bank is or may be subject, please refer to the factors discussed under the headings “Cautionary Note Regarding Forward-Looking Statements” and “Risk Factors,” in Medallion Bank’s Annual Report on Form 10-K for the year ended December 31, 2025 and Quarterly Reports on Form 10-Q for the quarters ended March 31, 2026 and June 30, 2026.

This press release does not constitute a notice of redemption with respect to the Series E Preferred Stock.

Company Contact

Investor Relations
212-328-2176
investorrelations@medallion.com

COMMACK, NY, Sept. 30, 2026 (GLOBE NEWSWIRE) — SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX) (“Scienture”), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through the development, commercialization, and distribution of novel specialty products that address unmet market needs, today announced that it has determined to effect a reverse stock split of its outstanding shares of common stock at a ratio of 1-for-25. The reverse stock split is expected to take effect before markets open on Monday, October 5, 2026. The Company’s common stock will continue to be traded on the Nasdaq Capital Market under the symbol “SCNX” and will begin trading on a split-adjusted basis when the market opens on Monday, October 5, 2026. The new CUSIP number for the Company’s common stock following the reverse stock split will be 80880X203. As of September 30, 2026, the Company has 41,064,146 shares of common stock issued and outstanding. Following the reverse stock split, the Company expects to have approximately 1,642,565 shares of common stock issued and outstanding.

The reverse stock split is intended to enable the Company to achieve several important corporate objectives, including enabling the Company to maintain compliance with the minimum bid price requirement under Nasdaq’s continued listing criteria and making additional shares of common stock available for future issuance.

At the effective time of the reverse stock split, every 25 shares of the Company’s issued and outstanding common stock will be converted automatically into one issued and outstanding share of common stock without any change in the par value per share. Stockholders holding shares through a brokerage account will have their shares automatically adjusted to reflect the 1-for-25 reverse stock split. The reverse split will not result in any change in the par value per share or the total number of authorized shares of common stock.

The reverse stock split will affect all stockholders uniformly and will not alter any stockholder’s percentage interest in the Company’s equity, except to the extent that the reverse stock split would result in a stockholder owning a fractional share. No fractional shares will be issued in connection with the reverse stock split. Stockholders of record otherwise entitled to receive a fractional shares as a result of the reverse stock split will receive a cash payment in lieu of such fractional share. Proportional adjustments will be made to the number of shares of the Company’s common stock issuable upon exercise or conversion of the Company’s equity awards, convertible preferred stock and warrants, as well as the applicable exercise or conversion price. Stockholders with shares in brokerage accounts should direct any questions concerning the reverse stock split to their broker; all other stockholders may direct questions to the Company’s transfer agent, Continental Stock Transfer & Trust Company.

About Scienture Holdings, Inc.

SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX), through its wholly owned subsidiary, Scienture, LLC, is a comprehensive pharmaceutical product company focused on providing enhanced value to patients, physicians and caregivers by offering novel specialty products to satisfy unmet market needs. Scienture, LLC is a branded, specialty pharmaceutical company consisting of a highly experienced team of industry professionals who are passionate about developing and bringing to market unique specialty products that provide enhanced value to patients and healthcare systems. The assets in development at Scienture are across therapeutics areas, indications and cater to different market segments and channels. For more information please visit: www.scientureholdings.com and www.scienture.com.

Cautionary Statements Regarding Forward-Looking Statements

This press release contains certain statements that may be deemed to be “forward-looking statements” within the federal securities laws, including the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Statements that are not historical are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements relate to future events or our future performance or future financial condition. These forward-looking statements are not historical facts, but rather are based on current expectations, estimates and projections about our company, our industry, our beliefs and our assumptions. Such forward-looking statements include, but are not limited to, statements regarding our or our management team’s expectations, hopes, beliefs, intentions or strategies regarding the future, including for the intended reverse stock split and the products we may launch, the success those products may have in the marketplace, and our strategies related to those products. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. In some cases, you can identify forward-looking statements by the following words: “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “ongoing,” “plan,” “potential,” “predict,” “project,” “should,” or the negative of these terms or other similar expressions, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements are subject to a number of risks and uncertainties (some of which are beyond our control) that may cause actual results or performance to be materially different from those expressed or implied by such forward-looking statements. Accordingly, readers should not place undue reliance on any forward-looking statements. These risks include risks relating to agreements with third parties; our ability to raise funding in the future, as needed, and the terms of such funding, including potential dilution caused thereby; our ability to continue as a going concern; security interests under certain of our credit arrangements; our ability to maintain the listing of our common stock on The Nasdaq Stock Market LLC; claims relating to alleged violations of intellectual property rights of others; the outcome of any current legal proceedings or future legal proceedings that may be instituted against us; unanticipated difficulties or expenditures relating to our business plan; and those risks detailed in our most recent Annual Report on Form 10-K, as amended, and subsequent reports filed with the Securities and Exchange Commission.

Forward-looking statements speak only as of the date they are made. Scienture Holdings, Inc. undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise that occur after that date, except as otherwise provided by law.

Contact:

SCIENTURE HOLDINGS, INC.
20 Austin Blvd
Commack, NY 11725
Email: IR@Scienture.com

HAMILTON, Bermuda, Sept. 30, 2026 (GLOBE NEWSWIRE) — American Overseas Group Limited (BSX: AORE.BH) (Pink Sheets: AOREF.PK) (“AOG” or the “Company”) today reported consolidated net income available to common shareholders of $1.6 million, or $33.60 per diluted share, for the three months ended June 30, 2026. This compares to consolidated net income available to common shareholders of $2.5 million, or $53.51 per diluted share, for the three months ended June 30, 2025. Book value per weighted share at June 30, 2026 was $1,338.04, an increase from the book value per weighted share of $1,139.67 at June 30, 2025.

For the three months ended June 30, 2026, net earned property and casualty premiums decreased $1.3 million from $12.8 million a year ago to $11.5 million.   

Quarter to Date fee income decreased $0.4 million from $5.4 million to $5.0 million and gross written premiums decreased $10.0 million, moving from $260.9 million to $250.9 million. Quarter to Date Loss and loss adjustment expenses as a percentage of earned premium increased from 58.3% to 63.3%.  

For the three months ended June 30, 2026, operating expenses increased $0.2 million from $3.3 million to $3.5 million.

As part of its ongoing capital management efforts, the Company will continue to redirect excess capital within the group to debt reduction. The Company reduced the outstanding principal balance of its 12% Senior Secured Notes by $6.5 million in the first half of 2026, reducing the balance of its 12% Notes to $4.1 million as of June 30, 2026, and reducing total outstanding debt to a balance of $9.4 million as of June 30, 2026. Additionally, the Company retired the remaining outstanding principal balance of its 12% Senior Secured Notes in the 3rd quarter of 2026, reducing total outstanding debt to a balance of $5.3 million, which is comprised of its 9% Series A Senior Secured Notes. The Company expects to take additional steps towards leverage reduction, followed by returned value to shareholders unless more compelling opportunities arise.

Forward-Looking Statements

This release contains statements that may be considered “forward-looking statements” within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements include, without limitation, the Company’s expectations respecting the volatility of its insured portfolio, losses, loss reserves and loss development, the adequacy and availability of its liquidity and capital resources, its current run off strategy, its strategy for writing other reinsurance businesses and its expense reduction measures. These statements are based on current expectations and the current views of the economic and operating environment and are not guarantees of future performance. A number of risks and uncertainties, including economic competitive conditions, could cause actual results to differ materially from those projected in forward-looking statements. The Company’s actual results could differ materially from those expressed or implied in the forward-looking statements.

Information About the Company

American Overseas Group Limited is an insurance holding company incorporated in Bermuda and a tax resident of the United Kingdom. Its operating subsidiaries provide specialty property/casualty insurance, reinsurance and insurance management services. More information can be found at www.aoreltd.com.

American Overseas Group Limited

info@aoreltd.com

American Overseas Group Limited
Consolidated Balance Sheets
(unaudited)
As of June 30, 2026 and December 31, 2025
(dollars in thousands)
								June 30, 2026					December 31, 2025
Assets
		Investments:
			Fixed-maturity securities held as available for sale, at fair value					$	153,356				$	161,312
			Equity investments held as available for sale, at fair value						1,053					1,041
		Cash and cash equivalents							54,331					45,140
		Restricted cash							1,691					843
		Accrued investment income							1,163					1,135
		Premiums receivable							212,973					211,993
		Deferred insurance premiums							320,614					299,720
		Reinsurance balances receivable, net							491,282					481,444
		Deferred policy acquisition costs							9,056					9,420
		Intangible assets							4,800					4,800
		Goodwill							33,050					33,050
		Other assets							6,545					5,373
			Total Assets					$	1,289,914				$	1,255,271
Liabilities and Equity
	Liabilities:
		Loss and loss expense reserve						$	475,640				$	465,401
		Deferred commission income							6,083					6,481
		Unearned premiums							332,231					311,073
		Ceded premium payable							235,087					233,727
		Payable to general agents							309					459
		Funds withheld							133,397					133,343
		Accounts payable and accrued liabilities							30,462					26,472
		Notes payable							9,360					15,833
		Non-owned interest in VIE							300					300
		Interest payable							119					435
		Deferred tax liability							4,066					3,413
			Total Liabilities						1,227,054					1,196,937
	Shareholders’ Equity:
		Common shares							4,698					4,698
		Additional paid-in capital							189,206					189,179
		Accumulated other comprehensive income (loss)							(2,292	)				(1,932	)
		Retained deficit							(128,752	)				(133,611	)
			Total Shareholders’ Equity						62,860					58,334
			Total Liabilities and Equity					$	1,289,914				$	1,255,271
		See Notes to June 30, 2026 Consolidated Financial Statements available on American Overseas Group Ltd. Website at www.aoreltd.com

	American Overseas Group Limited
	Consolidated Statements of Operations
	(unaudited)
	(dollars in thousands, except share and per share amounts)
									Three months ended June 30,								Six months ended June 30,
										2026				2025				2026				2025
		Revenues
			Net premiums earned						$	11,533			$	12,783			$	23,263			$	26,136
			Fee income							4,985				5,386				11,596				11,802
			Net investment income							544				472				1,014				962
			Net realized gains on investments							–				(6	)			(75	)			(6	)
			Other income							17				38				21				53
				Total revenues						17,079				18,673				35,819				38,947
		Expenses
			Losses and loss adjustment expenses							7,298				7,455				13,777				14,506
			Acquisition expenses							3,831				4,052				7,689				8,125
			Operating expenses							3,519				3,294				7,284				6,415
			Interest expense							333				578				768				1,157
				Total expenses						14,981				15,379				29,518				30,203
	Pre-tax net profit (loss)								$	2,098			$	3,294			$	6,301			$	8,744
			Income tax (expense)							(520	)			(780	)			(1,442	)			(1,977	)
	Net profit (loss) available to common shareholders									1,578				2,514				4,859				6,767
		Net profit (loss) per common share:
		Basic							$	33.60			$	53.51			$	103.41			$	144.04
		Diluted								33.60				53.51				103.41				144.04
		Weighted-average number of common shares outstanding:
		Basic								46,979				46,979				46,979				46,979
		Diluted								46,979				46,979				46,979				46,979
	See Notes to June 30, 2026 Consolidated Financial Statements available on American Overseas Group Ltd. Website at www.aoreltd.com

MOLINE, Ill., Sept. 30, 2026 (GLOBE NEWSWIRE) — QCR Holdings, Inc. (NASDAQ: QCRH) (“QCRH” or the “Company”) announced today that its third quarter ended September 30, 2026, financial results will be released after the market closes on Tuesday, October 20, 2026. The Company will host a conference call and webcast the next day, Wednesday, October 21, 2026, at 10:00 a.m. Central Time to discuss the results. Shareholders, analysts, and other interested parties are invited to join.

Teleconference
Dial-in information for the call is 888-346-9286 (international 412-317-5253). Participants should request to join the QCR Holdings, Inc. call. The event will be archived and available for replay through October 28, 2026. The replay access information is 855-669-9658 (international 412-317-0088); access code 5670385.

Webcast
A webcast of the teleconference can be accessed at the Company’s News and Events page at www.qcrh.com. An archived version of the webcast will be available at the same location shortly after the live event has ended.

About Us
QCR Holdings, Inc., headquartered in Moline, Illinois, is a relationship-driven, multi-bank holding company serving the Quad Cities, Cedar Rapids, Cedar Valley, Des Moines/Ankeny and Springfield communities through its wholly owned subsidiary banks. The banks provide full-service commercial and consumer banking and trust and wealth management services. Quad City Bank & Trust Company, based in Bettendorf, Iowa, commenced operations in 1994, Cedar Rapids Bank & Trust Company, based in Cedar Rapids, Iowa, commenced operations in 2001, Community State Bank, based in Ankeny, Iowa, was acquired by the Company in 2016, and Guaranty Bank, based in Springfield, Missouri, was acquired by the Company in 2018. Additionally, the Company serves the Waterloo/Cedar Falls, Iowa community through Community Bank & Trust, a division of Cedar Rapids Bank & Trust Company. The Company has 35 locations in Iowa, Missouri, and Illinois. As of June 30, 2026, the Company had $9.5 billion in assets, $7.0 billion in loans and $7.4 billion in deposits. For additional information, please visit the Company’s website at www.qcrh.com.

Contact
Doug Neumann
VP, Investor Relations
(309) 743-7753
dneumann@qcrh.com                                                                 

Clinical trial designed to demonstrate proof-of-concept for soquelitinib in the treatment of hidradenitis suppurativa and evaluate its effects on Th17 biology

SOUTH SAN FRANCISCO, Calif., Sept. 30, 2026 (GLOBE NEWSWIRE) — Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that enrollment has begun in its Phase 1b clinical trial of soquelitinib for the treatment of patients with hidradenitis suppurativa.

“The initiation of our Phase 1b hidradenitis suppurativa trial provides an important opportunity to expand the potential of soquelitinib to a wider range of diseases,” said Richard A. Miller, M.D., co-founder, president and chief executive officer of Corvus. “In addition to evaluating safety and efficacy, the trial is designed to evaluate soquelitinib’s ability to modulate Th17-driven disease, complementing the results we have already seen in Th2-driven diseases such as atopic dermatitis. Hidradenitis suppurativa is primarily driven by Th17 cells, which we have shown to be reduced in patients with atopic dermatitis treated with soquelitinib. We look forward to exploring the potential of selective ITK inhibition with soquelitinib to provide an oral and potentially more effective treatment option for hidradenitis suppurativa with a novel mechanism of action.”

The Phase 1b clinical trial is designed to enroll up to 25 patients 18 years and older with moderate to severe hidradenitis suppurativa. All patients will receive a soquelitinib dose of 200 mg twice per day for 12 weeks, followed by a 90-day follow-up period with no treatment. The primary endpoint of the trial is safety and tolerability. The key efficacy endpoint is the proportion of patients achieving Hidradenitis Suppurativa Clinical Response (HiSCR) 50/75 at week 12, and the trial will also evaluate skin and blood biomarkers.

This is the fourth indication under clinical development for soquelitinib, which is also in a registrational Phase 3 trial for relapsed/refractory peripheral T cell lymphoma (PTCL), a Phase 2 trial (SIERRA1) for moderate to severe atopic dermatitis (AD), and a Phase 2 trial for autoimmune lymphoproliferative syndrome (ALPS). Corvus also plans to initiate a Phase 2 clinical trial of soquelitinib in patients with asthma later this year.

About Corvus Pharmaceuticals
Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company pioneering the development of ITK inhibition as a new approach to immunotherapy for a broad range of immune diseases and cancer. The Company’s lead product candidate is soquelitinib, an investigational, oral, small molecule drug that selectively inhibits ITK. Soquelitinib is being evaluated in a registrational Phase 3 clinical trial for relapsed/refractory PTCL, a Phase 2 clinical trial for the treatment of atopic dermatitis, and a Phase 1b clinical trial for hidradenitis suppurativa. Its other clinical-stage candidates are being developed for a variety of cancer indications. For more information, visit www.corvuspharma.com or follow the Company on LinkedIn.

About Hidradenitis Suppurativa¹
Hidradenitis suppurativa (HS) is a chronic inflammatory skin condition characterized by painful lesions such as deep-seated nodules, abscesses, skin tunnels, and fibrotic scars. The condition’s impact extends beyond physical discomfort, with associated pain, drainage, malodor, and scarring often leading to profound negative psychosocial implications for affected individuals. Treatments include topical therapies, oral therapies, systemic injectable biologic therapies, and direct interventions. HS is associated with elevated levels of Th17 cells compared to regulatory T cells (Tregs), leading to high levels of IL-17 and other cytokines that cause inflammation.

About Soquelitinib
Soquelitinib (formerly CPI-818) is an investigational small molecule drug given orally designed to selectively inhibit ITK (interleukin-2-inducible T cell kinase), an enzyme that is expressed predominantly in T cells and plays a role in T cell and natural killer (NK) cell immune function. Soquelitinib has been shown to affect T cell differentiation and induce the generation of Th1 helper cells while blocking the development of both Th2 and Th17 cells and production of their secreted cytokines. Th1 T cells are required for immunity to tumors, viral infections, and other infectious diseases. Th2 and Th17 helper T cells are involved in the pathogenesis of many autoimmune and allergic diseases. Recent studies have demonstrated that ITK controls a switch between the differentiation of Th17 proinflammatory cells and T regulatory suppressor cells. Inhibition of ITK leads to a shift toward T regulatory cell differentiation, which has the potential to suppress autoimmune and inflammatory reactions. The Company believes the inhibition of specific molecular targets in T cells may be of therapeutic benefit for patients with autoimmune and allergic diseases and in cancers, including solid tumors. Based on results from a Phase 1/1b clinical trial in patients with refractory T cell lymphomas (published in Blood), which demonstrated tumor responses in very advanced, refractory, difficult to treat T cell malignancies, the Company is enrolling a registrational Phase 3 clinical trial (NCT06561048) of soquelitinib in patients with relapsed/refractory PTCL. Soquelitinib is also now being investigated in a randomized placebo-controlled Phase 2 clinical trial in patients with atopic dermatitis and a Phase 1b clinical trial in patients with hidradenitis suppurativa. A publication describing the chemistry, enzymology, and biology of soquelitinib appeared in npj Drug Discovery in December 2024 and is available online at the Nature website and on the Publications and Presentations page of the Corvus website.

Forward-Looking Statements
This press release contains forward-looking statements, including statements related to the potential safety, tolerability, clinical benefit, and efficacy of the Company’s product candidates, including soquelitinib; the potential use of soquelitinib to improve therapy for a broad range of patients with T cell lymphoma, atopic dermatitis, hidradenitis suppurativa, other immune diseases, and cancers; and clinical strategy and the design of clinical trials, including the timeline for initiation, target or expected number of patients to be enrolled, dose levels, and other product development milestones. All statements other than statements of historical fact contained in this press release are forward-looking statements. These statements often include words such as “believe,” “expect,” “anticipate,” “intend,” “plan,” “estimate,” “seek,” “will,” “may,” or similar expressions. Forward-looking statements are subject to a number of risks and uncertainties, many of which involve factors or circumstances that are beyond the Company’s control. The Company’s actual results could differ materially from those stated or implied in forward-looking statements due to a number of factors, including but not limited to, risks detailed in the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2026, filed with the Securities and Exchange Commission on August 6, 2026, as well as other documents that may be filed by the Company from time to time with the Securities and Exchange Commission. In particular, the following factors, among others, could cause results to differ materially from those expressed or implied by such forward-looking statements: the Company’s ability to demonstrate sufficient evidence of efficacy and safety in its clinical trials of its product candidates; the accuracy of the Company’s estimates relating to its ability to initiate and/or complete preclinical studies and clinical trials and release data from such studies and clinical trials; the results of preclinical studies and interim data from clinical trials not being predictive of future results; the Company’s ability to enroll sufficient numbers of patients in its clinical trials; the unpredictability of the regulatory process; regulatory developments in the United States and foreign countries; the costs of clinical trials may exceed expectations; and the Company’s ability to raise additional capital. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, it cannot guarantee that the events and circumstances reflected in the forward-looking statements will be achieved or occur, and the timing of events and circumstances and actual results could differ materially from those projected in the forward-looking statements. Accordingly, you should not place undue reliance on these forward-looking statements. All such statements speak only as of the date made, and the Company undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events, or otherwise.

INVESTOR CONTACT:
Zack Kubow
Vice President, Investor Relations and Corporate Communications
Corvus Pharmaceuticals, Inc.
investors@corvuspharma.com

MEDIA CONTACT:
Julia Stern
Real Chemistry
media@corvuspharma.com

^{_________________________
1} https://www.ncbi.nlm.nih.gov/books/NBK534867/